Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents nausea and vomiting. Sold as Sancuso, Sustol. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Granisetron (sold as Sancuso, Sustol), first approved Sep 12, 2008, with 0 new uses approved and 0 published complete response letters.
First approved: Sep 12, 2008
Applications: 2
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $10.5M
First approved in the EU: Apr 20, 2012
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Sancuso
Part D
$6.4M
-3%
1,064
Sustol
Part B
$3.8M
-43%
1,646
Granisetron HCL
Part B
$225K
-37%
15,324
Sustol
Part D
$144K
+29%
38
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
GRANISETRON HCL 1 MG TABLET: $1.28 per unitGeneric · -15% in a year
SANCUSO 3.1 MG/24 HR PATCH: $686.64 per unitBrand · +5% in a year
Approvals in the EU (EMA)
First approved in the EU 43 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
KytrilDrugs with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. · Taiyo Pharma Co., Ltd. · Feb 25, 2022
Kytril Fine GranuleDrugs with a new additional indication for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with radiation. · Chugai Pharmaceutical Co., Ltd. · Dec 22, 2011
Clinical Trials
10 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Apotex